Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi

FDA Approves Gamifant (emapalumab-lzsg) for Primary Hemophagocytic Lymphohistiocytosis https://t.co/YALlc0XdKh

Are you a US rheumatologist interested in what the midterm election results mean for us? 100 members of the next Congress are NEW and we need to meet them! Please invest in #RheumPAC NOW. Help advance arthritis research, reform step therapy & other causes! https://t.co/pcRkh6eLfJ

Sudden discontinuation of duloxetine may have Adverse Events in up to 44% - dizziness, nauseam headache, paresthesia, vomiting, irritability, nightmares. Instead, its rec to gradually reduce dose over 2 weeks before D/C of duloxetine.https://t.co/aSGU0CVldB

New Guidelines on CT pulm nodules-no F/U needed for solid nodules <6cm in low risk pts (age, smoking, morphology); but larger (6-8cm), suspicious nodules should have 6 and 12 mos F/U images. Some 8cm or more nodules require more freq assessments https://t.co/Nl6zV3VQg1

The Next Best Meeting in Rheumatology is coming - RHEUMNOW LIVE - March 22-24 2019 in beautiful downtown Fort Worth. Short Lectures, interactive sessions, Q&A panels, TED (like) Talks, digital, streaming and much more. You dont want to miss this meeting! https://t.co/5TVg0Frsbf

79 pts Ultrasound evidence of gout (tophus or double contour sign) @ knee or MTP1 were given ULT for 6 mos. Those achieving very low uric acid levels showed US decrease in tophus (r = 0.54) and double contour sign disappearance (r=−0.59) https://t.co/4W0EX8swDo

Large claims analysis shows that lipid screening was suboptimal (37%) among RA patients but was higher when RA patients visited a rheumatologist and a non-rheumatology clinicians (~55%). https://t.co/S4Op22LOoY

"Therapeutic Update: Biosimilars in Rheumatology" video series features nine experts talking about biosimilars, sponsored by Sandoz, Inc. Visit RheumNow to watch: https://t.co/1vmnEJqOSi #biosimilars

J Rheum (Ward et al) reports that the minimal clinically important improvement (MCII) of RAPID-3 was –3.8. https://t.co/UxCOeMl52g

2018 NRMP report shows Rheumatology as one of the most competitive fellowships with 313 applicants for 221 positions - 147 filled by US grads and 69 by FMGs. https://t.co/xRmMyA2yCy

Drug interactions with Xeljanz (tofacitinib) - CP3A4 (ketoconazole) & CYP2C19 Inhibitors (fluconazole) may increase TOFA exposure; CYP3A4 Inducers (rifampin) may reduce TOFA; do not combine with other immunosuppressants (AZA, CsA, tacrolimus) https://t.co/yrs7RBmn2P